A Phase 1 interventional study of Ubrogepant and Ubrogepant in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single oral dose A of ubrogepant on Day 1 under fasting conditions.
Drug: Ubrogepant
Participants will receive a single oral dose B of ubrogepant on Day 1 under fasting conditions.
Drug: Ubrogepant
Participants will receive a single oral dose C of ubrogepant on Day 1 under fasting conditions.
Drug: Ubrogepant
Participants will receive a single oral dose D of ubrogepant on Day 1 under fed conditions.
Drug: Ubrogepant
IRT Oral Tablet
ODT Oral Tablet
Number of Participants Experiencing Adverse Events
An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 33 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of Ubrogepant
AUCt of Ubrogepant
Time frame: Up to approximately 3 days
AUC From Time 0 to the Time Infinity (AUCinf) of Ubrogepant
AUCinf of Ubrogepant
Time frame: Up to approximately 3 days
Maximum Observed Plasma Concentration (Cmax) of Ubrogepant
Cmax of Ubrogepant
Time frame: Up to approximately 3 days
Time lag between dosing and drug to appear in systemic circulation following extravascular administration (Tlag) of Ubrogepant
Tlag of Ubrogepant
Time frame: Up to approximately 3 days
Time to maximum observed plasma concentration (Tmax) of Ubrogepant
Tmax of Ubrogepant
Time frame: Up to approximately 3 days
Apparent terminal phase elimination constant (λz) of Ubrogepant
λz of Ubrogepant
Time frame: Up to approximately 3 days
Terminal phase elimination half-life (t1/2) of Ubrogepant
t1/2 of Ubrogepant
Time frame: Up to approximately 3 days
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of Ubrogepant
CL/F of Ubrogepant
Time frame: Up to approximately 3 days
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of Ubrogepant
Vz/F of Ubrogepant
Time frame: Up to approximately 3 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2026 to primary completion in Oct 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ubrogepant